论文部分内容阅读
背景与目的:乳腺癌早期即可发生播散和转移,远处转移尤其骨转移是影响患者预后的主要因素之一,而骨髓微转移用常规方法又难以检测出来。本研究旨在探讨检测乳腺癌患者骨髓中CK19mRNA的表达及其临床意义。方法:应用RT鄄PCR技术,同时对照检测65例乳腺癌患者、15例乳腺良性病变患者和8例健康人骨髓中的CK19mRNA表达,并分析CK19mRNA表达与临床病理因素的关系。结果:65例乳腺癌患者中,22例CK19mRNA阳性,阳性率为33.8%;乳腺良性病变患者和健康人骨髓中未检测到CK19mRNA表达。CK19mRNA表达与乳腺癌肿瘤大小和分期有关(P<0.05),与年龄和淋巴结转移状况无显著性相关(P>0.05);与外周血中CEA异常增高呈正相关(r=0.372,P=0.002)。结论:CK19mRNA可作为检测乳腺癌患者骨髓微转移的分子指标之一,可为乳腺癌患者的治疗和预后判断提供帮助。
BACKGROUND & OBJECTIVE: Breast cancer can be disseminated and metastasized in the early stage. Distal metastasis, especially bone metastasis, is one of the main factors affecting the prognosis of patients. However, it is difficult to detect bone marrow micrometastases by conventional methods. This study aimed to investigate the expression of CK19mRNA in bone marrow of patients with breast cancer and its clinical significance. Methods: The mRNA of CK19mRNA in 65 patients with breast cancer, 15 patients with benign breast lesions and 8 healthy controls were detected by RT-PCR. The relationship between CK19mRNA and clinicopathologic factors was analyzed. Results: Of the 65 breast cancer patients, CK19 mRNA was positive in 22 cases and the positive rate was 33.8%. No CK19 mRNA was detected in the bone marrow of patients with benign breast diseases and healthy people. The expression of CK19mRNA was correlated with tumor size and stage (P <0.05), but not with age and lymph node metastasis (P> 0.05), but positively correlated with abnormal CEA in peripheral blood (r = 0.372, P = 0.002) . Conclusion: CK19mRNA can be used as one of the molecular markers for the detection of bone marrow micrometastasis in breast cancer patients, which may be helpful to the treatment and prognosis of breast cancer patients.